Cross-Talk of Focal Adhesion-Related Gene Defines Prognosis and the Immune Microenvironment in Gastric Cancer

Deli Mao, Rui Xu, Hengxing Chen, Xiancong Chen, Dongsheng Li, Shenglei Song, Yulong He, Zhewei Wei, Changhua ZhangFrontiers in Cell and Developmental Biology 2021 · DOI

TL;DR

This study investigates the role of focal adhesion-related genes in gastric cancer (GC) by analyzing genetic and transcriptional data. They developed a "focal adhesion index" (FAI) that correlates with prognosis, immune infiltration, and drug sensitivity, suggesting these genes are key biomarkers for GC.

What Problem Does This Paper Address?

Gastric cancer (GC) is a complex and deadly disease, and understanding the molecular mechanisms driving its progression is crucial for improving patient outcomes. The focal adhesion pathway is known to be involved in tumor invasion, migration, and drug resistance. However, its comprehensive role in the GC microenvironment, immune cell infiltration, and drug sensitivity, particularly through the interplay of multiple genes, remained largely unexplored. This paper aims to fill this gap by systematically analyzing focal adhesion-related genes from both genetic and transcriptional perspectives to identify their impact on GC prognosis and the tumor microenvironment.

Methods

The researchers employed a multi-omics approach, integrating data from The Cancer Genome Atlas (TCGA) and the Gene-Expression Omnibus (GEO) databases. Key methods included:

  • Data Acquisition and Processing: Standard bioinformatics pipelines were used to process somatic mutation data, RNA-seq (FPKM to TPM conversion), and microarray data. Batch effects were corrected using the "sva" package.
  • Focal Adhesion Index (FAI) Construction: A novel FAI was developed by analyzing the expression of 18 prognosis-related focal adhesion genes. This index was used to stratify patients into high and low FAI groups.
  • Subtype Identification: Consensus clustering was applied to identify GC subtypes based on the expression of three key focal adhesion genes (FLT1, EGF, and COL5A2).
  • Prognostic Signature Development: A LASSO Cox regression model was used to build a prognostic signature incorporating focal adhesion genes and M2 macrophage expression.
  • Functional Enrichment Analysis: Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) were used to explore the signaling pathways associated with different FAI subtypes and risk groups.
  • Drug Sensitivity Analysis: Correlations between FAI and drug sensitivity (IC50 values) were analyzed using data from the Genomics of Drug Sensitivity in Cancer (GDSC) database.
  • Statistical Analysis: Standard statistical methods like Kaplan-Meier curves, Chi-square tests, Wilcoxon tests, and Pearson's correlation were employed.

Datasets

  • TCGA-STAD: Used for somatic mutation data, RNA-seq (FPKM), and clinical information. This served as the primary training dataset.
  • GEO Datasets (GSE66229 and GSE15459): Used for gene expression data and clinical information, serving as validation datasets.
  • GDSC Database: Used for drug sensitivity analysis of GC cell lines.

The study did not introduce new benchmark datasets but rather utilized publicly available, well-established resources.

Key Insights and Ideas

  • Focal Adhesion Genes as Oncogenes: Mutations in focal adhesion-related genes, surprisingly, were associated with longer survival times. This suggests these genes might act as tumor suppressors in their mutated form, or that mutations in these genes are a marker of a less aggressive tumor biology.
  • FAI as a Multifaceted Biomarker: The FAI is not just a prognostic indicator but also reflects the tumor's immune microenvironment (higher M2 macrophage infiltration in high FAI), epithelial-mesenchymal transition (EMT) status, and even sensitivity to specific targeted therapies (e.g., ALK, cell cycle, BMX inhibitors).
  • Immune Microenvironment Link: High FAI is strongly associated with increased infiltration of M2 macrophages and regulatory T cells (Tregs), and enrichment of immune-related signaling pathways. This highlights the critical role of focal adhesion in shaping the tumor's immune landscape.
  • Molecular Subtyping: Three specific focal adhesion genes (FLT1, EGF, and COL5A2) can effectively distinguish GC subtypes with distinct prognostic outcomes, offering a new way to stratify patients.
  • Prognostic Signature Integration: Combining focal adhesion genes with M2 macrophage expression into a risk signature provides a robust tool for predicting GC patient survival, outperforming traditional clinicopathological features alone.

Key Results

  • Mutations in focal adhesion-related genes were associated with significantly longer survival in GC patients (P = 1.263E-7).
  • Patients with multiple gene mutations in the focal adhesion pathway had better survival than those with single mutations or no mutations (P < 0.001).
  • High FAI was significantly associated with shorter survival time across TCGA and validation cohorts (e.g., P = 3.091E-3 in TCGA).
  • High FAI was linked to increased M2 macrophage infiltration (CD163, MRC1 markers) and enrichment of immune and EMT signaling pathways.
  • The developed prognostic signature showed good predictive performance, with AUC values for 1, 3, and 5-year survival ranging from 0.613 to 0.891 across datasets.
  • The FAI was found to predict sensitivity to ALK, cell cycle, and BMX inhibitors, and resistance to BRAF and MET inhibitors.

Limitations and Future Work

  • Bioinformatics-Based Findings: The study relies heavily on bioinformatics analysis of public datasets. The authors acknowledge the need for more experimental validation and clinical sample studies to confirm their findings.
  • Mechanism Elucidation: While the study identifies associations, the precise molecular mechanisms by which focal adhesion genes influence the immune microenvironment and drug sensitivity require further investigation.
  • Limited Mutation Rate: The mutation rate of individual focal adhesion genes was generally low, which might limit the power of mutation-based analyses for some genes.
  • Future Directions: The authors suggest that FAI and the developed prognostic signature can serve as valuable biomarkers for guiding immunotherapy and personalized treatment strategies in GC. Further research should focus on validating these findings experimentally and in larger, diverse patient cohorts.

Summary updated

Abstract

<b>Background:</b> Focal adhesion, as the intermediary between tumor cells and extracellular matrix communication, plays a variety of roles in tumor invasion, migration, and drug resistance. However, the potential role of focal adhesion-related genes in the microenvironment, immune cell infiltration, and drug sensitivity of gastric cancer (GC) has not yet been revealed. <b>Methods:</b> The genetic and transcriptional perspectives of focal adhesion-related genes were systematically analyzed. From a genetic perspective, the focal adhesion index (FAI) was constructed based on 18 prognosis-related focus adhesion-related genes to evaluate the immune microenvironment and drug sensitivity. Then three prognosis-related genes were used for consistent clustering to identify GC subtypes. Finally, use FLT1, EGF, COL5A2, and M2 macrophages to develop risk signatures, and establish a nomogram together with clinicopathological characteristics. <b>Results:</b> Mutations in the focal adhesion-related gene affect the survival time and clinical characteristics of GC patients. FAI has been associated with a shorter survival time, immune signaling pathways, M2 macrophage infiltration, epithelial-mesenchymal transition (EMT) signaling, and diffuse type of GC. FAI recognizes ALK, cell cycle, and BMX signaling pathways inhibitors as sensitive agents for the treatment of GC. FLT1, EGF, and COL5A2 may distinguish GC subtypes. The established risk signature is of great significance to the prognostic evaluation of GC based on FLT1, EGF, and COL5A2 and M2 macrophage expression. <b>Conclusion:</b> The focal adhesion-related gene is a potential biomarker for the evaluation of the immune microenvironment and prognosis. This work emphasizes the potential impact of the focal adhesion pathway in GC therapy and highlights its guiding role in prognostic evaluation.
BibTeX
@inproceedings{mao2021cross,
  author = {Deli Mao and Rui Xu and Hengxing Chen and Xiancong Chen and Dongsheng Li and Shenglei Song and Yulong He and Zhewei Wei and Changhua Zhang},
  title = {{Cross-Talk of Focal Adhesion-Related Gene Defines Prognosis and the Immune Microenvironment in Gastric Cancer}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.716461},
}
Figure